Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

NCT05609942 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated - alignment of strategic priorities

Conditions

Advanced Systemic Mastocytosis

Interventions

DRUG: BLU-263
DRUG: Azacitidine

Sponsor

Blueprint Medicines Corporation